Overactive bladder (OAB) significantly impacts the quality of life of patients, with treatment often involving both behavioral and pharmacological approaches. The most common pharmacological treatments are anticholinergic agents, but these can be limited by tolerability, efficacy, and long-term compliance. Recent advancements in understanding OAB’s pathophysiology have led to the development of alternative treatments like mirabegron and botulinum toxin. These treatments offer different mechanisms of action and avoid the common side effects associated with anticholinergic medications.

Research supports the efficacy of anticholinergics, mirabegron, and botulinum toxin for managing OAB. However, long-term compliance with anticholinergics is often poor due to side effects. Mirabegron and botulinum toxin provide additional options, especially for patients who cannot tolerate or have not responded to anticholinergics. These newer agents have distinct mechanisms, improving the range of treatment options available for OAB management while addressing issues of efficacy and side effects.

Reference: Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2013;6:1-16. doi: 10.2147/RRU.S40034.